Designing a Head-to-Head Trial in IPF. Pulmonary Clinical Trials Conference. 2026. Graham CS, et al. [Oral Presentation]
Previous
Previous
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Next
Next